Can Drugs Targeting Tumor Microenvironment Unleash Cancer Vaccine Potential?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cancer vaccines in the past have failed clinically but may have succeeded biologically, according to Roche R&D exec Hy Levitsky. The immunosuppressive tumor microenvironment must be circumvented if the vaccine response is to be effective – and Roche thinks its immuno-oncology pipeline could do the trick.